A Phase 4 Study Evaluating the Safety of the Nasal Pump
Conditions: Dry Eye; Kerato Conjunctivitis Sicca Interventions: Drug: Tyrvaya Nasal Pump Sponsors: Oyster Point Pharma, Inc. Active, not recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 26, 2024 Category: Research Source Type: clinical trials

Johnson & Johnson's Nipocalimab Granted U.S. FDA Fast Track Designation to Reduce the Risk of Fetal Neonatal Alloimmune Thrombocytopenia (FNAIT) in Alloimmunized Pregnant Adults
SPRING HOUSE, Pa. March 26, 2024– Johnson& Johnson announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation (FTD) for nipocalimab to reduce the risk of FNAIT in alloimmunizeda pregnant adults... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - March 26, 2024 Category: Pharmaceuticals Source Type: clinical trials

Tonix Pharmaceuticals Receives Rare Pediatric Disease Designation from the FDA for TNX-2900 for the Treatment of Prader-Willi Syndrome
CHATHAM, N.J., March 25, 2024 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a biopharmaceutical company with marketed products and a pipeline of development candidates, today announced the U.S. Food... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - March 25, 2024 Category: Pharmaceuticals Source Type: clinical trials

Phase 2b Study Evaluating the Safety and Efficacy of AP01 in Participants With PPF
Conditions: Progressive Pulmonary Fibrosis Interventions: Drug: AP01; Other: Placebo Sponsors: Avalyn Pharma Inc.; DevPro Biopharma Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 25, 2024 Category: Research Source Type: clinical trials

A Study Evaluating the Safety and Efficacy of AP01 in Participants With Progressive Pulmonary Fibrosis (PPF)
Conditions: Progressive Pulmonary Fibrosis Interventions: Drug: AP01; Other: Placebo Sponsors: Avalyn Pharma Inc.; DevPro Biopharma Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 25, 2024 Category: Research Source Type: clinical trials

Axsome Therapeutics Announces AXS-12 Achieves Primary Endpoint in the SYMPHONY Phase 3 Trial in Narcolepsy
NEW YORK, March 25, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced that AXS-12... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - March 25, 2024 Category: Pharmaceuticals Source Type: clinical trials

Axsome Therapeutics Announces Results of CRESCENDO Narcolepsy Patient Survey Demonstrating Unmet Needs in Treated Narcolepsy Type 1 Patients
NEW YORK, March 25, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced topline... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - March 25, 2024 Category: Pharmaceuticals Source Type: clinical trials

Stoke Therapeutics Announces Landmark New Data That Support the Potential for STK-001 to be the First Disease-Modifying Medicine for the Treatment of Patients with Dravet Syndrome
BEDFORD, Mass.--(BUSINESS WIRE)--Mar. 25, 2024-- Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - March 25, 2024 Category: Pharmaceuticals Source Type: clinical trials

Invivyd Announces FDA Authorization for Emergency Use of Pemgarda (Formerly VYD222) for Pre-Exposure Prophylaxis (PrEP) of COVID-19
WALTHAM, Mass., March 22, 2024 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company on a mission to protect the vulnerable from serious viral infectious diseases, today announced that Pemgarda™ (pemivibart), formerly... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - March 22, 2024 Category: Pharmaceuticals Source Type: clinical trials

Otsuka Announces Interim Data from Phase 2b/c Trial Indicating New Investigational Compound May Shorten Tuberculosis Treatment
Princeton, N.J. and Tokyo, Japan– March 21, 2024– Otsuka Pharmaceutical Development& Commercialization, Inc., and our parent company Otsuka Pharmaceutical, Co. Ltd., announce that interim data from a Phase 2b/c trial exploring... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - March 21, 2024 Category: Pharmaceuticals Source Type: clinical trials

Lisata Therapeutics Announces U.S. FDA Rare Pediatric Disease Designation Granted to LSTA1 for the Treatment of Osteosarcoma
BASKING RIDGE, N.J., March 21, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the“Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - March 21, 2024 Category: Pharmaceuticals Source Type: clinical trials

Lisata Therapeutics Announces U.S. FDA Rare Pediatric Disease Designation Granted to LSTA1 for the Treatment of Osteosarcoma
BASKING RIDGE, N.J., March 21, 2024. Lisata Therapeutics, Inc. (“Lisata” or the“Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - March 21, 2024 Category: Pharmaceuticals Source Type: clinical trials

HI-Bio Receives FDA Orphan Drug Designation for Felzartamab for the Treatment of Antibody-Mediated Rejection (AMR) in Kidney Transplant Recipients
SOUTH SAN FRANCISCO, Calif.,– March 21, 2024– Human Immunology Biosciences (HI-Bio™), a clinical-stage biotechnology company developing targeted therapies for patients with severe immune-mediated diseases (IMDs), today announced... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - March 21, 2024 Category: Pharmaceuticals Source Type: clinical trials

Ibex Presents New Data from Multiple Studies Showcasing Accuracy of AI in Prostate, Breast and Gastric Cancer Diagnosis
BOSTON, March 21, 2024. Ibex Medical Analytics (Ibex), the leader in AI-powered cancer diagnostics, today announced excellent results across multiple clinical studies conducted with the University of Pittsburgh Medical Center (UPMC), Brigham and... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - March 21, 2024 Category: Pharmaceuticals Source Type: clinical trials

Inflammation-Reducing Drug Minocycline Shows No Benefit For Dry Age-Related Macular Degeneration in NIH Trial
March 20, 2024 -- The drug minocycline, an antibiotic that also decreases inflammation, failed to slow vision loss or expansion of geographic atrophy in people with dry age-related macular degeneration (AMD), according to a phase II clinical study... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - March 20, 2024 Category: Pharmaceuticals Source Type: clinical trials